Search Results - "Suda, Margaret"

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements by NISHINO, Mizuki, GIOBBIE-HURDER, Anita, GARGANO, Maria, SUDA, Margaret, RAMAIYA, Nikhil H, HODI, F. Stephen

“…Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements,…”
Get full text

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? by Nishino, Mizuki, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H, Hodi, F Stephen

“…Investigate the impact of the reduction of the number of target lesions on immune-related response assessment in advanced melanoma patients treated with…”
Get full text

Developing a Common Language for Tumor Response to Immunotherapy: Immune-related Response Criteria using Unidimentional measurements by Nishino, Mizuki, Giobbie-Hurder, Anita, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H., Hodi, F. Stephen

Get full text

A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT for locally advanced squamous cancer of the head and neck (LASCCHN) by Tishler, Roy B., Lorch, Jochen H., Sher, David J, Clark, John Ross, Chan, Annie W, Suda, Margaret, Balboni, Tracy A., Busse, Paul M., Haddad, Robert I., Wirth, Lori J.

“…Abstract only 5579 Background: We studied escalating doses of weekly nab-paclitaxel (Abraxane, AB) combined with weekly carboplatin (CP) and daily IMRT in…”
Get full text

A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC) by Lorch, Jochen H., Busaidy, Naifa, Ruan, Daniel T, Janne, Pasi A., Limaye, Sewanti Atul, Wirth, Lori J., Barletta, Justine A., Rabinowits, Guilherme, Garraway, Levi A., Van Allen, Eliezer Mendel, Wagle, Nikhil, Hanna, Glenn J., Misiukiewicz, Krzysztof, Suda, Margaret, Haddad, Tyler C, Devine, Catherine E, Williams, Amy, Warsi, Ghulam, Posner, Marshall R., Haddad, Robert I.

“…Abstract only 6023 Background: We present results of an open label phase II study of the mTOR inhibitor Everolimus in patients (pts) with RAIR TC. Methods: Pts…”
Get full text